Pfizer Inc

NYSE: PFE
$29.23
-$0.04 (-0.1%)
Closing Price on October 18, 2024

PFE Articles

These four stocks may not be as safe as U.S. Treasury debt, but they still would make great additions to more conservative growth and income portfolios now.
Pfizer announced early on Monday that it received a couple critical updates from the FDA related to its Xalkori (crizotinib).
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
The U.S. Food and Drug Administration on Thursday published a list of brand-name drug companies that the agency has received complaints against for obstructing development of generic versions of...
UnitedHealth, Walmart, Pfizer, and DowDuPont did their best to pin a small gain on the Dow Monday.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Pfizer, Merck, McDonald's, and Coca-Cola were the big losers Tuesday among the 30 Dow stocks.
Pfizer reported mixed first-quarter financial results and full-year guidance before the markets opened on Tuesday.
Both Pfizer and Merck are scheduled to release their most recent quarterly results before the markets open on Tuesday. These are the two biggest companies in the pharma industry and they can set the...
24/7 Wall St. has put together a preview of Apple, McDonald's, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Pfizer shares were relatively muted after the pharma giant provided an update for its late-stage kidney trial.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.